Mycophenolate mofetil for the prevention and treatment of graft-versus-host disease following stem cell transplantation: Preliminary findings

Bone Marrow Transplantation

Volumn 27, Issue 12, 2001, Pages 1255-1262

  Vogelsang, G B ^a   Arai, S ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Graft versus host disease; Mycophenolate mofetil; Prevention; Review; Stem cell transplantation; Treatment

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; DRUG METABOLITE; FLUDARABINE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY S5; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISOLONE; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ACUTE DISEASE; ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW SUPPRESSION; CHIMERA; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOG; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TARGETING; GASTROINTESTINAL DISEASE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMATOLOGIC DISEASE; HEMATOPOIESIS; HUMAN; INCIDENCE; LIVER TOXICITY; LYMPHOCYTE ACTIVATION; MORBIDITY; MORTALITY; MOUSE; MULTICENTER STUDY; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; ORGAN TRANSPLANTATION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RAT; SIDE EFFECT; STEM CELL TRANSPLANTATION; WHOLE BODY RADIATION;

ANIMALS; CLINICAL TRIALS; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYCOPHENOLIC ACID; TRANSPLANTATION, HOMOLOGOUS; TRANSPLANTS;

EID: 0034933004     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703076     Document Type: Article

References (36)

1. Effect of HLA incompatibility in marrow transplantation from unrelated and HLA-mismatched related donors
2. Prevention and treatment of acute graft-versus-host disease: The old and the new
3. Prophylaxis and treatment of acute graft-versus-host disease: Current state, implications of new immunopharmacologic compounds and future strategies to prevent and treat acute GVHD in high-risk patients
4. Immunomodulators: Immunosuppressive agents and immunostimulants
5. Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: Role of deoxyguanosine nucleotide depletion
6. Preliminary risk-benefit assessment of mycophenolate mofetil in transplant rejection
7. Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression in renal transplant recipients
8. Mycophenolate-update after it has come of age
9. Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation
10. Intravenous mycophenolate mofetil plus prednisolone and cyclosporine in the prophylaxis of GVHD after stem cell transplantation
11. Efficacy and safety of mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant recipient
12. Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus
13. Mycophenolate mofetil in renal allograft recipients
14. Mycophenolate mofetil - Clinical and experimental experience
15. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients
16. A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil in primary adult liver transplant recipients. An interim report
17. Mycophenolate mofetil
18. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection
19. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation
20. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients
21. Administration of mycophenolate mofetil in a murine model of acute graft-versus-host disease after bone marrow transplantation
22. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immuno-suppression after marrow transplantation
23. Haploidentical stem cell allografts after nonmyeloablative therapy in a preclinical large animal model
24. Synergism between mycophenolate mofetil and cyclosporine in preventing graft-versus-host disease among lethally irradiated dogs given DLA-nonidentical unrelated marrow grafts
25. Intravenous mycophenolate mofetil (MMF) after allogeneic blood stem cell transplantation. Results of a dose-finding study
26. Mycophenolate mofetil for the prophylaxis of acute GVHD in HLA-mismatched bone marrow transplant recipients
27. Outpatient allografting with minimally myelosuppressive, immunosuppressive conditioning of low-dose TBI and postgrafting cyclosporine (CSP) and mycophenolate mofetil (MMF)
28. Hematopoietic stem cell transplants (HSCT) from HLA-matched and 1-allele mismatched unrelated donors using a nonmyeloablative regimen
29. Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients
30. Intravenous mycophenolate mofetil plus prednisolone and cyclosporine in the prophylaxis of GVHD after stem cell transplantation
31. Mycophenolate mofetil in the treatment of acute and chronic GVHD in bone marrow transplant patients: Three years' experience
32. Treatment of resistant acute and chronic graft versus host disease with mycophenolate mofetil
33. Treatment of acute and chronic graft versus host disease with mycophenolate mofetil
34. The use of mycophenolate mofetil in the treatment of refractory chronic graft versus host disease
35. Salvage therapy with mycophenolate mofetil (MMF) for patients with severe chronic GVHD
36. Mycophenolate mofetil (MMF) for the treatment of chronic graft versus host disease (cGVHD) of the liver